Hong Kong stock movement: WuXi AppTec rises 12.22%, performance guidance significantly exceeds expectations boosting stock price

Hong Kong Stock Movement

WuXi AppTec rose by 12.22%. Based on recent key news:

1. On August 3, WuXi AppTec raised its full-year performance guidance for 2026, expecting revenue to increase from RMB 51.3-53 billion to 58.5-60.5 billion, with the year-on-year growth rate of continuing operations revenue raised from 18%-22% to 35%-39%. This adjustment exceeded market expectations, driving the stock price up. Source: Jin10 Data

2. On August 3, WuXi AppTec released its semi-annual report, showing a net profit of RMB 11.08 billion in the first half of the year, a year-on-year increase of 33.7%. The company plans to distribute an interim dividend of RMB 5.1 per 10 shares, an increase of 45.7% compared to the same period last year. Strong performance supports the rise in stock price. Source: WuXi AppTec official website

3. On August 3, WuXi AppTec announced the acceleration of its global capacity layout, starting the construction of a new base in Changzhou ahead of schedule, with capital expenditure budget raised to RMB 7.5-8.5 billion. This move demonstrates the company's confidence in future growth, further boosting the stock price. Source: Zhitong Finance Global innovative drug mergers and acquisitions are active, benefiting the industry.

Stocks with High Trading Volume in the Industry

WuXi Biologics rose by 3.92%, with a trading volume of HKD 155 million, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and specific reasons need further observation.

WuXi AppTec rose by 4.79%, with a trading volume of HKD 45.39 million, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and specific reasons need further observation.

Genscript Biotech rose by 2.33%, with a trading volume of HKD 20.32 million, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and specific reasons need further observation.

Stocks with High Market Capitalization in the Industry

Crown Bioscience rose by 5.29%. Based on recent key news:

1. On August 3, two business segments of Crown Bioscience have not yet achieved profitability, leading to increased operational pressure. Revenue from large molecules and cell and gene therapy services decreased by 11% year-on-year, with gross margin dropping to -92.80%, and clinical research service gross margin falling to 7.10%, affecting stock price volatility.

2. On August 3, changes in Crown Bioscience's debt structure attracted market attention. Short-term loans increased by over 65%, and non-current liabilities due within one year surged more than seven times, significantly increasing the scale of debts that need to be repaid or renewed, adding financial pressure.

3. On August 3, policy catalysts drove a recovery in CXO sector sentiment, with a significant increase in CDMO orders leading to performance growth expectations. Global biotech financing is recovering, new orders are accelerating, and the proportion of CDMO business is increasing, showing signs of operational recovery. The CXO industry is highly cyclical, and the financing environment has a significant impact